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242 The impact of a referral pathway on management of CFRD
M. Rezaie, K. Bailey, J. Lee, L. Speight, R.I. Ketchell. 1. Adult CF Centre, Cardiff, United Kingdom.
There has been an increase in diagnosis of CFRD & IGT which may lead to a decline in pulmonary
function (PF). This has been shown in our centre following the introduction of Annual Review (AR)
since June 2005.
Aim: To develop a referral pathway for the management of CFRD.
Methods: A multidisciplinary approach was used involving CF and Diabetic Team (DT). The
WHO protocol for OGTT formed the basis of the pathway. Three categories were deﬁned; normal,
IGT&CFRD. The IGT were classiﬁed into 2 groups; clinically stable & deteriorating (decrease weight
and PF). Clinically stable patients monitored pre & post prandial for 2 weeks. Those with normal
Blood Glucose Levels (BGL) had a repeat OGTT in a year. Those with normal pre, but raised post
BGL were referred to the CF dietitian (CFD); those with raised pre & post BGL were referred to the
DT&CFD. Deteriorating & CFRD patients were referred to the DT, CFD & were quarterly reviewed
in a joint CF/DM clinic.
Results: see tables 1&2.
Conclusion: Following the implementation of care pathway, there has been no evidence of an
accelerated decline in PF of our diabetic population. This indicates provision of systematic referral
pathway for CFRD leads to integration of CF and DT yielding improved patient management and
optimised outcome.
Table 1: Patients Demographics
Total No. Existing DM New DM IGT Normal
164 (100m) 29 (14m) 21 (9m) 34 (21m)* 80 (56m)
Median age 25 25 30 23 25
Age range 16−62 18−47 20−47 18−48 16−62
Mean BMI 22.5 20.8 22.4 22.3 23
*Subsequent AR showed 10/34 IGT patients reverted to NGT
Table 2: Changes in patients’ PF at subsequent AR
PF CFRD IGT Normal
Improved 46% 35% 35%
Declined 44% 50% 40%
Unchanged 10% 15% 25%
243 Overﬁlling in pancreatic enzyme preparations: still an unresolved
issue
R. Foresti, L. Peloso, M. Anelli. Eurand spa, Milano, Italy
Given their inherent instability, all currently available Pancreatic Enzyme Prepara-
tions (PEPs) contain an “overﬁll”, in order to assure – at the end of their shelf life –
at least 90% of the label lipase activity. The USP currently allows overﬁlls up to
65%.
The actual lipase activity of a PEP capsule labeled at 10,000 IU, therefore, might
theoretically vary – according to its “freshness” – from 9,000 to 16,500 units.
This variation in potency can potentially lead to efﬁcacy issues, which may cause
increased pill burden, unnecessary drug associations to compensate for loss of
efﬁcacy or “product switching”.
The FDA also noted the potential safety risk posed by overﬁlling and, in a recently
published Guidance, it imposed a zero overﬁll for all PEPs to be marketed in the
USA after April 2008.
The overﬁll issue was ﬁrst studied by Whitehead who – after analysing several
commercially available PEPs – reported overﬁlls ranging from 14 to 39%.
We recently run a similar series of tests on 16 PEPs currently available in Europe
and in the USA and found overﬁll ranging from 7% to 47%, with a median value
of 32%. Since the PEPs analysed were on average 10−12 months old, the actual
amount of overﬁll was probably underestimated.
Our ﬁndings conﬁrm those reported earlier by Whitehead and suggest that none of
the currently available PEPs complies with the zero overﬁll requirement of the FDA
Guidance and, therefore, highlight a potential cause of suboptimal therapy with the
currently available PEPs.
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244 On which foods can pancreatic enzyme preparations (PEPs) be
sprinkled?
D. Shepherd2, R. Foresti1, D. Sica1, M. Anelli1. 1Eurand Spa, Milano, Italy;
2Eurand Inc, Vandalia, OH, USA
In very young children with Exocrine Pancreatic Insufﬁciency it is a common
practice to open the dosage units and to sprinkle their content on a small amount of
food. The most commonly used food is “applesauce”, since its acidic pH preserves
the coating of gastroprotected formulations which in turn prevents the degradation
of the enzymes in the stomach. Since the coating of most enteric coated formulations
starts dissolving at pH values above 5.5, it is safe to assume that all foods with
pH 5 could be used as a “vehicle” for PEP particles.
We tested 26 different baby and infant foods commercially available in the US
market and we found that 17 of them (66%) had a pH suitable for sprinkling. In
order to obtain additional evidence on the suitability of this pH based approach,
we tested also the “resistance” of three batches of EUR-1008 microtablets (a novel
enteric coated PEP) on another series of commercially available foods. The foods
tested included two simulations of “homemade recipes”, one with apple and one
with banana, both with the addition of sugar and lemon juice. We considered as
“suitable” those foods where EUR-1008 microtablets could remain for at least one
hour, without any signiﬁcant deterioration of the gastroresistant coating.
Ten out of eleven (91%) foods, including both homemade recipes, proved to be
suitable for the sprinkling/mixing of EUR-1008 microtablets.
Even though parents and caregivers should pay some attention to the foods they
sprinkle the content of the PEP capsules on, in most cases where the “universally
recommended applesauce” is not a feasible option, several other commercially
available foods and even “homemade recipes” could be used as an alternative.
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The study compared fat malabsorption and clinical symptoms in patients with CF
before and after treatment with EUR-1008, a novel pancreatic enzyme formulation.
Study design: The multicenter, open label trial involved a 7d dose stabilization period
and a 7d treatment period. Patients were switched from baseline enzyme treatment
without wash-out.
Inclusion criteria:
1. age <7 y in acceptable nutritional status
2. conﬁrmed CF and EPI,
3. no acute conditions
4. written informed consent
Exclusion criteria:
1. history or diagnosis of ﬁbrosing colonopathy, hyperuricemia, hyperuricosuria or
DIOS
2. recent use of immunosuppressive drugs, steroids or antibiotics
3. organ transplant or bowel surgery
4. hepatic insufﬁciency, hyperglycemia or CF-related diabetes
Results: 19 patients (12M, mean age 3.9, range 1−6) completed all phases of the study.
The percentage of “responders” – patients without steatorrhea and signs and symptoms
of malabsorption – was 52.6 at baseline, 68.4 (p = 0.375 vs base) after stabilization and
57.9 (p = 0.999 vs base) at the end of the study. Frequency and oily stools showed a
signiﬁcant decrease vs. baseline at end of study.
Physicians characterized patients as “improved” for 37% patients and “unchanged” in
63% at the end of the treatment phase. Parents characterized their children as 47%
“improved” and 53% “unchanged”. No signiﬁcant laboratory abnormalities or drug
related adverse events occurred during the treatment phase.
Conclusion: EUR-1008 is an effective, safe, and well tolerated in the treatment of EPI
in young CF patients.
